Please assess the completion status of the following clinical trial:

Trial Title: Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Gender: men and women~2. Ethnicity: all ethnic groups~3. Language: English~4. Age: ≥ 18 to 75 years~5. Type II diabetes~   * Currently treated with MDI (basal/bolus regimen) for at least 6 months~  * MDI must consist of three or more injections of insulin per day, with at least 2 injections being prandial/rapid-acting insulin~  * Prandial insulin restricted to insulin aspart, glulisine, and lispro~  * Basal insulin restricted to long acting once-daily analogues (insulin glargine U- 100, insulin degludec (U-100 or U-200), or insulin glargine U-300)~  * A1C within 30 days of randomization must be ≤ 7.5% on the present therapy~  * Less than or equal to 120 units of total insulin therapy per day~6. Ability to provide informed consent before any trial-related activities. Trial-related activities are any procedure that would not have been performed during normal management of the subject.~Exclusion Criteria:~1. GAD-65 antibody positive~2. Current glucocorticoid therapy greater than 5 mg of daily prednisone (or equivalent dose of other glucocorticoid)~3. Known or suspected allergy to trial medication(s), excipients, or related products, i.e., GLP-1RA therapy or insulin aspart or insulin degludec.~4. The receipt of any investigational drug within 90 days prior to this trial.~5. Previous participation in this trial (Randomized)~6. Mental incapacity or language barrier (non-English speaking)~7. Use of incretin-based therapies \<3 months before inclusion in the study~   * DPP-4 inhibitors sitagliptin, saxagliptin, linagliptin, alogliptin~  * GLP-1RA (exenatide, liraglutide, exenatide LAR, dulaglutide, albiglutide, lixisenatide, semaglutide)~  * GLP-1RA/Basal Insulin combination (IGlarLixi, IDegLira)~8. Present use of oral anti-diabetic agents other than metformin and SGLT-2i. The dose of metformin and/or SGLT-2i must be unchanged and stable for the immediate 3 months prior to baseline.~9. Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate contraceptive measures~10. Personal or family history of medullary thyroid carcinoma~11. Personal or family history of Multiple Endocrine Neoplasia syndrome type 2~12. History of acute or chronic pancreatitis, severe liver disease or LFT's \> 2.5X ULN, or severe disease of digestive tract~13. History of bariatric surgery/procedure (gastric banding, gastric sleeve, or Roux-en-Y)~14. Known elevation of serum calcitonin \> 50 ng/L

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Once-weekly sc semaglutide combined with once-daily insulin (Type: EXPERIMENTAL): Patients randomized to continue with MDI will be transitioned from their existing regimen to the rapid-acting insulin product insulin aspart and their basal insulin switched to once-daily insulin degludec.
- MDI requiring multiple daily injections of insulin (Type: EXPERIMENTAL): Patients randomized to MDI will be allowed to continue correction rapid-acting insulin, in addition to their prandial doses of rapid-acting insulin, throughout the duration of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).